DUPONT MERCK NEUROLITE IMAGING AGENT FOR SPECT STROKE DIAGNOSIS APPROVED
This article was originally published in The Gray Sheet
Executive Summary
DUPONT MERCK NEUROLITE IMAGING AGENT FOR SPECT STROKE DIAGNOSIS APPROVED Nov. 29 by FDA. The Neurolite (technetium 99m bicisate injection) kit is indicated for use in single-photon emission computed tomography (SPECT) as an adjunct to conventional computed tomography (CT) or magnetic resonance imaging (MRI) "in the location of stroke in patients in whom stroke has already been diagnosed," FDA's approval letter states. The drug "is not indicated for assessment of functional viability of brain tissue or for distinguishing between stroke and other brain lesions," the letter adds.